stockportfolio.pro
Stocks / AMLX vs NEO
AMLX vs NEO
Amylyx Pharmaceuticals, Inc. and NeoGenomics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Amylyx Pharmaceuticals, Inc. (AMLX) | NeoGenomics, Inc. (NEO) | |
|---|---|---|
| Market cap | $1.5B | $1.5B |
| Revenue (latest FY) | $0 | $727.33M |
| Net income (latest FY) | $-144.74M | $-108.03M |
| Revenue growth (5y CAGR) | — | 10.4% |
| Net margin | — | -14.9% |
| Return on equity | -47.4% | -12.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 3 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AMLX — free Open NEO — freeFrequently asked questions
Which is bigger, AMLX or NEO?
Amylyx Pharmaceuticals, Inc. is larger by market capitalization — $1.5B versus $1.5B.
Which grows faster, AMLX or NEO?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.